Advertisement
Canada markets close in 2 hours 32 minutes

  • S&P/TSX

    21,744.76
    -43.72 (-0.20%)
     

  • S&P 500

    5,464.89
    -4.41 (-0.08%)
     

  • DOW

    39,138.78
    +26.62 (+0.07%)
     

  • CAD/USD

    0.7302
    -0.0021 (-0.28%)
     

  • CRUDE OIL

    81.25
    +0.42 (+0.52%)
     

  • Bitcoin CAD

    83,516.96
    -1,006.90 (-1.19%)
     

  • CMC Crypto 200

    1,262.72
    -21.07 (-1.64%)
     

  • GOLD FUTURES

    2,314.00
    -16.80 (-0.72%)
     

  • RUSSELL 2000

    2,015.32
    -7.03 (-0.35%)
     

  • 10-Yr Bond

    4.3040
    +0.0660 (+1.56%)
     

  • NASDAQ

    17,743.15
    +25.50 (+0.14%)
     

  • VOLATILITY

    12.69
    -0.15 (-1.17%)
     

  • FTSE

    8,225.33
    -22.46 (-0.27%)
     

  • NIKKEI 225

    39,667.07
    +493.92 (+1.26%)
     

  • CAD/EUR

    0.6829
    -0.0003 (-0.04%)
     
MARKETS LIVE BLOG:

STOCKS WOBBLE AS INVESTORS ON WATCH FOR CUES

Rivian stock soars after Volkswagen says it'll invest up to US$5 billion in JV

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Praxis Precision Medicines, Inc.
·2 min read
Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc.

BOSTON, May 17, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming conferences.

  • Praxis management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference, taking place in New York, NY at the NASDAQ Stock Exchange on May 20, 2024 at 10:00am EDT. A live webcast of the fireside chat will be available through this link and will also be available through the “Upcoming & Recent Events” page of the Investors + Media section of the company’s website www.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 90 days following the event.

  • Praxis management will also participate in the Mizuho Securities USA Neuroscience Summit, taking place in Boston, MA on May 21, 2024.

  • Praxis management will also be participating in a fireside chat at the Jefferies Global Healthcare Conference, taking place in New York, NY on June 6, 2024 at 11:30am EDT. A live webcast of the fireside chat will be available through this link and will also be available through the “Upcoming & Recent Events” page of the Investors + Media section of the company’s website www.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 90 days following the event.

About Praxis  
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.

ADVERTISEMENT
CONTACT: Investor Contact:  Praxis Precision Medicines  investors@praxismedicines.com  857-702-9452  Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576